Cutaneous Inflammation

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%

Competitive Landscape

1 companies ranked by most advanced pipeline stage

GSK
GSKLONDON, United Kingdom
1 program
1
TalarozolePhase 1Small Molecule1 trial
Active Trials
NCT00719121Completed12Est. Mar 2007

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKTalarozole

Clinical Trials (1)

Total enrollment: 12 patients across 1 trials

NCT00719121GSKTalarozole

Study on Anti-inflammatory Effects of Topical R115866 Gel

Start: Nov 2006Est. completion: Mar 200712 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space